15.02.2017 Medios AG  DE000A1MMCC8

DGAP-Adhoc: Medios AG reports an increase in revenue and profit for fiscal year 2016


 
DGAP-Ad-hoc: Medios AG / Key word(s): Preliminary Results Medios AG reports an increase in revenue and profit for fiscal year 2016 15-Feb-2017 / 10:28 CET/CEST Disclosure of an inside information acc. to Article 17 MAR, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Medios AG reports an increase in revenue and profit for fiscal year 2016 Berlin, February 15, 2017 - Medios AG, an expert pharmaceutical partner and solution provider in the Specialty Pharma segment, announces that its two subsidiary companies have developed very positively in the 2016 fiscal year. According to provisional figures (IFRS), Medios Pharma GmbH and Medios Manufaktur GmbH experienced a significant increase in revenues and profit compared to the previous year: Medios Pharma GmbH - Sales revenue increased by 119% to EUR 127.5 m (prior year EUR 58.2 m) - EBIT* increased by 268% to EUR 3.92 m (prior year EUR 1.06 m) Medios Manufaktur GmbH - Sales revenue increased by 23% to EUR 43.5 m (prior year EUR 35.3 m) - EBIT* increased by 16.5% to EUR 2.34 m (prior year EUR 2 m) Because both subsidiaries are to be consolidated only for the period of time after the contribution due to the contribution occurring during the course of the year in accordance with IFRS, the management board is additionally providing provisional pro forma figures (IFRS) for fiscal year 2016 for the purpose of comparisons. According to this information, Medios AG recorded an increase in revenue and profit compared to the prior year: - Consolidated sales revenue pro forma increased by 78% to EUR 160.5 m (prior year EUR 90.1 m**) - Consolidated EBIT* pro forma increased by 100.4% to EUR 5.67 m (prior year EUR 2.83 m**) The provisional IFRS results for the 2016 consolidated annual financial statements are not yet available. * EBIT is defined as the earnings before income tax minus interest income plus interest expense ** According to securities prospectus of November 16, 2016 Medios AG Matthias Gärtner, board member About Medios AG Medios AG, along with its subsidiaries Medios Pharma GmbH and Medios Manufaktur GmbH, has positioned itself in the specialty pharma segment as the go-to source for expertise and solutions. It brings together individual market players in a network of cooperating partners. Our objective is to ensure that patients have optimum access to pharmaceutical drugs and to offer integrated solutions along the value-added chain to partners and customers. Specialty pharmaceutical drugs are medications for patients with rare and/or chronic illnesses (for example, certain cancer, autoimmune diseases, and infectious diseases) that require lengthy and expensive customised treatment. Contact Medios AG Matthias Gärtner Friedrichstraße 113a 10117 Berlin Phone: +49 30 232 5668 0 Fax: +49 30 232 5668 66 E-Mail: [email protected] www.medios.ag Disclaimer This notification contains forward-looking statements that are subject to certain risks and uncertainties. Future results may significantly deviate from currently expected results, specifically due to various risk factors and uncertainties such as changes in business, economic, and competitive circumstances, exchange rate fluctuations, uncertainties about legal disputes or investigations, and the availability of financial resources. Medios AG assumes no responsibility whatsoever for updating the forward- looking statements contained in this notification. --------------------------------------------------------------------------- 15-Feb-2017 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de --------------------------------------------------------------------------- Language: English Company: Medios AG Friedrichstraße 113a 10117 Berlin Germany Phone: +49 30 232 566 - 800 Fax: 030 / 8321 8377 E-mail: [email protected] Internet: www.medios.ag ISIN: DE000A1MMCC8 WKN: A1MMCC Listed: Regulated Market in Frankfurt (General Standard), Hamburg; Regulated Unofficial Market in Dusseldorf End of Announcement DGAP News Service --------------------------------------------------------------------------- 544627 15-Feb-2017 CET/CEST


Die wichtigsten Finanzdaten auf einen Blick
  2017 2018 2019 2020 2021 2022 2023e
Umsatzerlöse1 253,64 327,83 516,80 626,54 1.357,41 1.610,78 1.874,70
EBITDA1,2 7,29 8,54 16,37 13,09 34,64 51,21 52,41
EBITDA-Marge3 2,87 2,61 3,17 2,09 2,55 3,18
EBIT1,4 6,80 7,40 14,39 9,54 15,26 28,97 31,37
EBIT-Marge5 2,68 2,26 2,78 1,52 1,12 1,80 1,67
Jahresüberschuss1 4,13 4,33 7,76 6,06 7,40 18,33 18,81
Netto-Marge6 1,63 1,32 1,50 0,97 0,55 1,14 1,00
Cashflow1,7 0,82 -3,14 -0,45 -38,12 61,52 37,12 16,41
Ergebnis je Aktie8 0,32 0,31 0,65 0,38 0,37 0,77 0,79
Dividende8 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2023 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: Baker Tilly

INVESTOR-INFORMATIONEN
©boersengefluester.de
Medios
WKN Kurs in € Einschätzung Börsenwert in Mio. €
A1MMCC 14,100 Halten 335,66
KGV 2025e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
9,86 31,18 0,32 33,10
KBV KCV KUV EV/EBITDA
0,72 20,46 0,18 5,38
Dividende '22 in € Dividende '23e in € Div.-Rendite '23e
in %
Hauptversammlung
0,00 0,00 0,00 26.06.2024
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
07.05.2024 13.08.2024 12.11.2024 27.03.2024
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
-6,31% -8,99% -11,10% -20,96%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu Medios AG  ISIN: DE000A1MMCC8 können Sie bei EQS abrufen


Gesundheit , A1MMCC , ILM1 , XETR:ILM1